A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA

by Laurie H. Sehn, Maurizio Martelli, Marek Trněný, Wenxin Liu, Christopher R. Bolen, Andrea Knapp, Deniz Sahin, Gila Sellam, Umberto Vitolo
Published 2020-06-01

Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial

by Franck Morschhauser, Nilanjan Ghosh, Izidore S. Lossos, M. Lia Palomba, Amitkumar Mehta, Olivier Casasnovas, Don Stevens, Sudhakar Katakam, Andrea Knapp, Tina Nielsen, Ron McCord, Gilles Salles
Published 2021-08-01